Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

1.

Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Ogura M, Hatake K, Tobinai K, Uchida T, Suzuki T, Terui Y, Yokoyama M, Maruyama D, Mori M, Jewell RC, Katsura K, Hotta T.

Jpn J Clin Oncol. 2013 May;43(5):466-75. doi: 10.1093/jjco/hyt022. Epub 2013 Feb 28.

PMID:
23456745
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T.

Blood. 2008 Feb 1;111(3):1094-100. Epub 2007 Nov 14.

PMID:
18003886
[PubMed - indexed for MEDLINE]
Free Article
3.

A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

Ogawa Y, Ogura M, Suzuki T, Ando K, Uchida T, Shirasugi Y, Tobinai K, Lee JH, Kase M, Katsura K, Hotta T.

Int J Hematol. 2013 Aug;98(2):164-70. doi: 10.1007/s12185-013-1393-x. Epub 2013 Jul 12.

PMID:
23846385
[PubMed - indexed for MEDLINE]
4.

Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.

Nightingale G.

Ann Pharmacother. 2011 Oct;45(10):1248-55. doi: 10.1345/aph.1P780. Epub 2011 Sep 6. Review.

PMID:
21896924
[PubMed - indexed for MEDLINE]
5.

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg M, Petersen J, Losic N, Radford J.

Blood. 2008 Jun 15;111(12):5486-95. doi: 10.1182/blood-2007-10-117671. Epub 2008 Apr 4.

PMID:
18390837
[PubMed - indexed for MEDLINE]
Free Article
6.

Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study.

Coiffier B, Losic N, Rønn BB, Lepretre S, Pedersen LM, Gadeberg O, Frederiksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Robak T, Petersen J.

Br J Haematol. 2010 Jul;150(1):58-71. doi: 10.1111/j.1365-2141.2010.08193.x. Epub 2010 Apr 16.

PMID:
20408846
[PubMed - indexed for MEDLINE]
7.

Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Reagan JL, Castillo JJ.

Expert Rev Anticancer Ther. 2011 Feb;11(2):151-60. doi: 10.1586/era.10.223. Review.

PMID:
21342032
[PubMed - indexed for MEDLINE]
8.

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators.

J Clin Oncol. 2010 Apr 1;28(10):1749-55. doi: 10.1200/JCO.2009.25.3187. Epub 2010 Mar 1. Erratum in: J Clin Oncol. 2010 Aug 1;28(22):3670.

PMID:
20194866
[PubMed - indexed for MEDLINE]
Free Article
9.

Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.

O'Brien S, Osterborg A.

Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):361-8. doi: 10.3816/CLML.2010.n.069. Review.

PMID:
21030349
[PubMed - indexed for MEDLINE]
10.

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.

Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R.

Clin Cancer Res. 2010 Sep 1;16(17):4331-8. doi: 10.1158/1078-0432.CCR-10-0570. Epub 2010 Jul 2.

PMID:
20601446
[PubMed - indexed for MEDLINE]
Free Article
11.

Ofatumumab in the treatment of chronic lymphocytic leukemia.

Tsimberidou AM.

Drugs Today (Barc). 2010 Jul;46(7):451-61. doi: 10.1358/dot.2010.46.7.1497416. Review.

PMID:
20683500
[PubMed - indexed for MEDLINE]
12.

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.

Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, Ohtsu T, Igarashi T, Sasaki Y, Kinoshita T, Murate T.

Ann Oncol. 1998 May;9(5):527-34.

PMID:
9653494
[PubMed - indexed for MEDLINE]
Free Article
13.
14.

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008079. doi: 10.1002/14651858.CD008079.pub2. Review.

PMID:
23152253
[PubMed - indexed for MEDLINE]
15.

A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.

Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, Lisby S; 415 study investigators.

Br J Haematol. 2013 Nov;163(3):334-42. doi: 10.1111/bjh.12537. Epub 2013 Aug 23. Erratum in: Br J Haematol. 2014 May;165(3):422. Verhoef, Gregor [added].

PMID:
24032456
[PubMed - indexed for MEDLINE]
16.

Ofatumumab.

Sanford M, McCormack PL.

Drugs. 2010 May 28;70(8):1013-9. doi: 10.2165/11203850-000000000-00000. Review.

PMID:
20481657
[PubMed - indexed for MEDLINE]
17.

Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.

Barth MJ, Czuczman MS.

Future Oncol. 2013 Dec;9(12):1829-39. doi: 10.2217/fon.13.219.

PMID:
24295413
[PubMed - indexed for MEDLINE]
18.

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW.

J Clin Oncol. 2001 Apr 15;19(8):2153-64.

PMID:
11304767
[PubMed - indexed for MEDLINE]
Free Article
19.

Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.

Schweighofer CD, Tuchscherer A, Sperka S, Meyer T, Rattel B, Stein S, Ismail S, Elter T, Staib P, Reiser M, Hallek M.

Cancer Immunol Immunother. 2012 Dec;61(12):2367-73. doi: 10.1007/s00262-012-1362-x. Epub 2012 Oct 23.

PMID:
23090290
[PubMed - indexed for MEDLINE]
20.

Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.

Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, Maruyama D, Suzuki T, Mori M, Kasai M, Cronier D, Wooldridge JE, Koshiji M.

Cancer Sci. 2011 Feb;102(2):432-8. doi: 10.1111/j.1349-7006.2010.01809.x. Epub 2011 Jan 12.

PMID:
21205069
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk